Preliminary Evidence of the Differential Expression of Human Endogenous Retroviruses in Kawasaki Disease and SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 Oct 2023
Historique:
received: 23 08 2023
revised: 03 10 2023
accepted: 04 10 2023
medline: 30 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

Multisystem inflammatory syndrome in children (MIS-C) is a postinfectious sequela of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with some clinical features overlapping with Kawasaki disease (KD). Our research group and others have highlighted that the spike protein of SARS-CoV-2 can trigger the activation of human endogenous retroviruses (HERVs), which in turn induces inflammatory and immune reactions, suggesting HERVs as contributing factors in COVID-19 immunopathology. With the aim to identify new factors involved in the processes underlying KD and MIS-C, we analysed the transcriptional levels of HERVs, HERV-related genes, and immune mediators in children during the acute and subacute phases compared with COVID-19 paediatric patients and healthy controls. The results showed higher levels of HERV-W, HERV-K, Syn-1, and ASCT-1/2 in KD, MIS-C, and COV patients, while higher levels of Syn-2 and MFSD2A were found only in MIS-C patients. Moreover, KD and MIS-C shared the dysregulation of several inflammatory and regulatory cytokines. Interestingly, in MIS-C patients, negative correlations have been found between HERV-W and IL-10 and between Syn-2 and IL-10, while positive correlations have been found between HERV-K and IL-10. In addition, HERV-W expression positively correlated with the C-reactive protein. This pilot study supports the role of HERVs in inflammatory diseases, suggesting their interplay with the immune system in this setting. The elevated expression of Syn-2 and MFSD2A seems to be a distinctive trait of MIS-C patients, allowing to distinguish them from KD ones. The understanding of pathological mechanisms can lead to the best available treatment for these two diseases, limiting complications and serious outcomes.

Identifiants

pubmed: 37894766
pii: ijms242015086
doi: 10.3390/ijms242015086
pmc: PMC10606856
pii:
doi:

Substances chimiques

Interleukin-10 130068-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : HORIZONHLTH-2021-DISEASE project (Personalized medicine and infectious disease: understanding the individual host response to virus) of the European Commission under the Horizon Europe Framework Program.
ID : G.A.101057302.

Références

Mob DNA. 2018 Dec 18;9:36
pubmed: 30568734
Viruses. 2022 May 07;14(5):
pubmed: 35632738
Biol Psychiatry. 2008 Dec 15;64(12):1019-23
pubmed: 18760403
Nature. 2000 Feb 17;403(6771):785-9
pubmed: 10693809
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
Retrovirology. 2008 Jan 23;5:6
pubmed: 18215254
MMWR Morb Mortal Wkly Rep. 2020 Oct 02;69(39):1404-1409
pubmed: 33001872
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Front Microbiol. 2023 May 22;14:1155624
pubmed: 37283924
J Immunol. 2020 Aug 15;205(4):892-898
pubmed: 32651218
Gastroenterol Hepatol. 2021 Jan;44(1):1-12
pubmed: 33039171
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
Front Pediatr. 2020 Dec 16;8:626182
pubmed: 33425823
Front Immunol. 2019 Sep 26;10:2244
pubmed: 31616420
Mol Cell Biol. 2003 May;23(10):3566-74
pubmed: 12724415
Int J Mol Sci. 2019 Nov 30;20(23):
pubmed: 31801288
Int J Mol Sci. 2021 Jul 13;22(14):
pubmed: 34299101
J Immunol. 2006 Jun 15;176(12):7636-44
pubmed: 16751411
Clin Rev Allergy Immunol. 2010 Aug;39(1):51-61
pubmed: 19697163
EBioMedicine. 2021 Apr;66:103341
pubmed: 33867312
iScience. 2023 May 19;26(5):106604
pubmed: 37091988
Innate Immun. 2021 Oct;27(7-8):503-513
pubmed: 34806446
Oncotarget. 2017 Feb 14;8(7):11249-11258
pubmed: 28061462
Heliyon. 2020 Oct;6(10):e05143
pubmed: 33024851
Nat Rev Microbiol. 2019 Jun;17(6):355-370
pubmed: 30962577
PLoS One. 2022 Nov 30;17(11):e0266336
pubmed: 36449533
J Rheumatol. 2006 Jan;33(1):16-23
pubmed: 16395745
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20534-9
pubmed: 18077339
JCI Insight. 2017 Sep 7;2(17):
pubmed: 28878130
Retrovirology. 2022 Nov 30;19(1):26
pubmed: 36451209
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Science. 2016 Mar 4;351(6277):1083-7
pubmed: 26941318
J Virol Methods. 2009 Oct;161(1):98-106
pubmed: 19505508
Curr Opin Genet Dev. 2000 Dec;10(6):651-5
pubmed: 11088016
PeerJ. 2019 Apr 5;7:e6711
pubmed: 30984482
Viruses. 2020 Jun 13;12(6):
pubmed: 32545816
Arthritis Rheumatol. 2022 Apr;74(4):e1-e20
pubmed: 35118829
Placenta. 2021 Sep 15;113:8-14
pubmed: 33504453
Brain Behav Immun. 2023 Jan;107:242-252
pubmed: 36270439
Placenta. 2013 Jan;34(1):85-8
pubmed: 23177091
Euro Surveill. 2020 Dec;25(48):
pubmed: 33272357
Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):7952-7
pubmed: 24843117
Curr Allergy Asthma Rep. 2022 May;22(5):53-60
pubmed: 35314921
Int J Mol Sci. 2022 Sep 03;23(17):
pubmed: 36077506
Curr Diab Rep. 2019 Nov 21;19(12):141
pubmed: 31754894
Lancet Infect Dis. 2020 Nov;20(11):e276-e288
pubmed: 32818434
Immunology. 2020 Jul;160(3):261-268
pubmed: 32460357
J Gen Virol. 2015 Jun;96(Pt 6):1207-1218
pubmed: 26068187
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
FASEB J. 2020 Jul;34(7):9419-9432
pubmed: 32501590
Biol Reprod. 2010 Sep;83(3):387-95
pubmed: 20484742
Pathogens. 2023 Jan 19;12(2):
pubmed: 36839434
Front Immunol. 2018 Sep 10;9:2039
pubmed: 30250470
Curr Pediatr Rep. 2022;10(2):19-30
pubmed: 35540721
PLoS One. 2013 Aug 07;8(8):e70399
pubmed: 23950929
Pediatr Rheumatol Online J. 2016 Apr 12;14(1):22
pubmed: 27068134
J Pediatr. 2018 Feb;193:147-154.e2
pubmed: 29212623
Ann Neurol. 2001 Oct;50(4):434-42
pubmed: 11601494
Viruses. 2017 May 31;9(6):
pubmed: 28561791
Retrovirology. 2013 Feb 09;10:16
pubmed: 23394165
Semin Cancer Biol. 2018 Dec;53:17-30
pubmed: 30317035
Hosp Pediatr. 2020 Jun;10(6):537-540
pubmed: 32265235
Ann Rheum Dis. 2020 Aug;79(8):993-995
pubmed: 32571869
Med Microbiol Immunol. 2023 Feb;212(1):3-12
pubmed: 36396785
Microbiome. 2022 Apr 22;10(1):65
pubmed: 35459226

Auteurs

Emanuela Balestrieri (E)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Elena Corinaldesi (E)

Pediatric Unit, Ramazzini Hospital, 41012 Carpi, Italy.

Marianna Fabi (M)

Pediatric Emergency Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40126 Bologna, Italy.

Chiara Cipriani (C)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Martina Giudice (M)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Allegra Conti (A)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.

Antonella Minutolo (A)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Vita Petrone (V)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Marialaura Fanelli (M)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Martino Tony Miele (MT)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Laura Andreozzi (L)

Pediatric Emergency Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40126 Bologna, Italy.

Fiorentina Guida (F)

Pediatric Emergency Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40126 Bologna, Italy.

Emanuele Filice (E)

Pediatric Emergency Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40126 Bologna, Italy.

Matteo Meli (M)

Pediatric Emergency Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40126 Bologna, Italy.

Sandro Grelli (S)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Guido Rasi (G)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Nicola Toschi (N)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Martinos Center for Biomedical Imaging and Harvard Medical School, Boston, MA 02129, USA.

Francesco Torcetta (F)

Pediatric Unit, Ramazzini Hospital, 41012 Carpi, Italy.

Claudia Matteucci (C)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Marcello Lanari (M)

Pediatric Emergency Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40126 Bologna, Italy.

Paola Sinibaldi-Vallebona (P)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
National Research Council, Institute of Translational Pharmacology, 00133 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH